<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01516580</url>
  </required_header>
  <id_info>
    <org_study_id>Inter B-NHL Ritux 2010 Phase 3</org_study_id>
    <secondary_id>2010-019224-31</secondary_id>
    <nct_id>NCT01516580</nct_id>
  </id_info>
  <brief_title>Intergroup Randomized Trial for Children or Adolescents With B-Cell Non Hodgkin Lymphoma or B-Acute Leukemia: Rituximab Evaluation in High Risk Patients</brief_title>
  <official_title>Intergroup Trial for Children or Adolescents With B-Cell Non Hodgkin Lymphoma or B-Acute Leukemia: Evaluation of Rituximab Efficacy and Safety in High Risk Patients - Phase III Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Gustave Roussy, Cancer Campus, Grand Paris</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Children's Oncology Group</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Gustave Roussy, Cancer Campus, Grand Paris</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of the trial is to test whether adding 6 injections of rituximab to standard
      &quot;Lymphome malin B&quot; LMB chemotherapy regimen improves the Event Free Survival (EFS) compared
      with LMB chemotherapy alone in children / adolescents with advanced stage B-cell Non-Hodgkin
      Lymphoma (NHL) / B-Acute Leukemia (B-AL)(stage III and LDH &gt; Nx2, any stage IV or B-AL).
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date>December 2011</start_date>
  <completion_date type="Anticipated">December 2021</completion_date>
  <primary_completion_date type="Actual">June 13, 2017</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Event free survival</measure>
    <time_frame>24 months</time_frame>
    <description>Minimum time to death from any cause, presence of viable cells in residue after [2nd (Rituximab-)CYVE], relapse, progressive disease, or second malignancy measured from randomization.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Survival</measure>
    <time_frame>5 years</time_frame>
    <description>Overall survival</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Acute toxicity</measure>
    <time_frame>6 months</time_frame>
    <description>Acute toxicity during treatment according to NCI-CTC V4</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Long term toxicity</measure>
    <time_frame>5 years</time_frame>
    <description>Long term toxicity, especially immune reconstitution, cardiac toxicity</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">482</enrollment>
  <condition>B-cell Non Hodgkin Lymphoma</condition>
  <condition>Mature B-cell Leukemia Burkitt-type</condition>
  <arm_group>
    <arm_group_label>LMB chemo</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Prephase (COP) for all groups followed by:
in group B: 4 courses: 2 COPADM + 2 CYM, with MTX 3g/m²
in group C: 6 courses: 2 COPADM + 2 CYVE + 2 maintenance courses, with MTX 8g/m², in 4h in C1, in 24h in C3 (except the 1st course) and CNS positive patients receive additional IT before each CYVE courses and HDMTX between CYVE courses.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>LMB chemo + Rituximab</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>LMB chemo as in the comparator arm Rituximab 375 mg/m² i.v.: 6 injections: two doses at 48h interval are given at D-2 and D1 of the 2 first courses (COPADM) and one dose at the beginning of the 2 following courses (CYM or CYVE).</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Vincristine, cyclophosphamide, methotrexate, doxorubicin, cytarabine, ara-C</intervention_name>
    <description>Prephase (COP) for all groups followed by:
in group B: 4 courses: 2 COPADM + 2 CYM, with MTX 3g/m² in group C: 6 courses: 2 COPADM + 2 CYVE + 2 maintenance courses, with MTX 8g/m², in 4h in C1, in 24h in C3 (except the 1st course) and CNS positive patients receive additional IT before each CYVE courses and HDMTX between CYVE courses.</description>
    <arm_group_label>LMB chemo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Rituximab, Vincristine, cyclophosphamide, methotrexate, doxorubicin, cytarabine, ara-C</intervention_name>
    <description>LMB chemo as in the comparator arm Rituximab 375 mg/m² i.v.: 6 injections: two doses at 48h interval are given at D-2 and D1 of the 2 first courses (COPADM) and one dose at the beginning of the 2 following courses (CYM or CYVE).</description>
    <arm_group_label>LMB chemo + Rituximab</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Histologically or cytologically proven B-cell malignancies, either Burkitt lymphoma or
             B-AL (=Burkitt leukaemia = L3-AL) or diffuse large B-cell NHL or aggressive mature
             B-cell NHL non other specified or specifiable.

          -  Stage III with elevated LDH level (&quot;B-high&quot;), [LDH &gt; twice the institutional upper
             limit of the adult normal values (&gt; Nx2)] or any stage IV or B-AL.

          -  6 months to less than 18 years of age at the time of consent.

          -  Males and females of reproductive potential must agree to use an effective
             contraceptive method during the treatment, and after the end of treatment: during
             twelve months for women, taking into account the characteristics of rituximab and
             during five months for men, taking into account the characteristics of methotrexate.

          -  Complete initial work-up within 8 days prior to treatment that allows definite
             staging.

          -  Able to comply with scheduled follow-up and with management of toxicity.

          -  Signed informed consent from patients and/or their parents or legal guardians

        Exclusion Criteria:

          -  Follicular lymphoma, MALT and nodular marginal zone are not included into this
             therapeutic study

          -  Patients with congenital immunodeficiency, chromosomal breakage syndrome, prior organ
             transplantation, previous malignancy of any type, or known positive HIV serology.

          -  Evidence of pregnancy or lactation period.

          -  There will be no exclusion criteria based on organ function.

          -  Past or current anti-cancer treatment except corticosteroids during less than one
             week.

          -  Tumor cell negative for CD20

          -  Prior exposure to rituximab.

          -  Severe active viral infection, especially hepatitis B.

          -  Hepatitis B carrier status history of HBV or positive serology.

          -  Participation in another investigational drug clinical trial.

          -  Patients who, for any reason, are not able to comply with the national legislation.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>6 Months</minimum_age>
    <maximum_age>17 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Véronique MINARD, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Institut Gustave Roussy, Villejuif, FRANCE</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Thomas GROSS, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Children Oncology Group, USA</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University Hospitals Leuven</name>
      <address>
        <city>Leuven</city>
        <zip>3000</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Children Oncology Group Operations centres</name>
      <address>
        <city>Monrovia</city>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The University of Hong Kong (Clinical Trials Centre)</name>
      <address>
        <city>Hong-Kong</city>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Institut de Cancérologie Gustave roussy</name>
      <address>
        <city>Villejuif</city>
        <zip>94805</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>2nd Dept. of Pediatrics Semmelweis Univ.</name>
      <address>
        <city>Budapest</city>
        <zip>1094</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Associazione Italiana di Ematologia ed Oncologia Pediatrica</name>
      <address>
        <city>Padova</city>
        <zip>35128</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Emma Children's Hospital</name>
      <address>
        <city>Amsterdam</city>
        <zip>1105 AZ</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Rectorat of Medical University</name>
      <address>
        <city>Wroclaw</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sociedad Española de Hematología y Oncología Pediátricas</name>
      <address>
        <city>Valencia</city>
        <zip>46010</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Birmingham</name>
      <address>
        <city>Birmingham</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Belgium</country>
    <country>Canada</country>
    <country>China</country>
    <country>France</country>
    <country>Hungary</country>
    <country>Italy</country>
    <country>Netherlands</country>
    <country>Poland</country>
    <country>Spain</country>
    <country>United Kingdom</country>
  </location_countries>
  <link>
    <url>http://www.igr.fr</url>
    <description>Institute Gustave Roussy web site</description>
  </link>
  <verification_date>June 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 19, 2012</study_first_submitted>
  <study_first_submitted_qc>January 24, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 25, 2012</study_first_posted>
  <last_update_submitted>June 13, 2017</last_update_submitted>
  <last_update_submitted_qc>June 13, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">June 14, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphoma</mesh_term>
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Lymphoma, Non-Hodgkin</mesh_term>
    <mesh_term>Lymphoma, B-Cell</mesh_term>
    <mesh_term>Leukemia, B-Cell</mesh_term>
    <mesh_term>Leukemia, Lymphocytic, Chronic, B-Cell</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cyclophosphamide</mesh_term>
    <mesh_term>Methotrexate</mesh_term>
    <mesh_term>Cytarabine</mesh_term>
    <mesh_term>Rituximab</mesh_term>
    <mesh_term>Liposomal doxorubicin</mesh_term>
    <mesh_term>Doxorubicin</mesh_term>
    <mesh_term>Vincristine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

